Cargando…

The combined effect of metformin and mirabegron on diet‐induced obesity

Anti‐obesity medications act by suppressing energy intake (EI), promoting energy expenditure (EE), or both. Metformin (Met) and mirabegron (Mir) cause weight loss by targeting EI and EE, respectively. However, anti‐obesity effects during concurrent use of both have yet to be explored. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xin‐Yuan, Liu, Ying, Zhang, Xuan, Zhao, Ben‐Chi, Burley, George, Yang, Zhi‐Can, Luo, Yi, Li, An‐Qi, Zhang, Ruo‐Xin, Liu, Zhi‐Ying, Shi, Yan‐Chuan, Wang, Qiao‐Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928947/ https://www.ncbi.nlm.nih.gov/pubmed/36818016 http://dx.doi.org/10.1002/mco2.207

Ejemplares similares

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition
por: Zhao, Lin, et al.
Publicado: (2022)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats
por: Zhang, Xu, et al.
Publicado: (2015)

Mirabegron displays anticancer effects by globally browning adipose tissues
por: Sun, Xiaoting, et al.
Publicado: (2023)

Metformin Ameliorates Hepatic Steatosis and Inflammation without Altering Adipose Phenotype in Diet-Induced Obesity
por: Woo, Shih-Lung, et al.
Publicado: (2014)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Mirabegron: The most promising adipose tissue beiging agent
por: Bel, Jocelyn S., et al.
Publicado: (2021)

Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
por: Dąbrowska, Anna Maria, et al.
Publicado: (2023)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

dSec16 Acting in Insulin-like Peptide Producing Cells Controls Energy Homeostasis in Drosophila
por: Zhang, Ruo-Xin, et al.
Publicado: (2022)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Respiratory dysfunction following initiation of mirabegron: A case report
por: Malsin, Elizabeth S., et al.
Publicado: (2019)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Metformin attenuates hypothalamic inflammation via downregulation of RIPK1-independent microglial necroptosis in diet-induced obese mice
por: Li, Xuan, et al.
Publicado: (2021)

Transcriptome Analysis of Liver Cancer Cell Huh-7 Treated With Metformin
por: Li, Chun-Qing, et al.
Publicado: (2022)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women
por: Halverson, Thomas, et al.
Publicado: (2022)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Metformin Alleviates Steatohepatitis in Diet-Induced Obese Mice in a SIRT1-Dependent Way
por: Guo, Wan-rong, et al.
Publicado: (2021)

How Do Structurally Distinct Compounds Exert Functionally Identical Effects in Combating Obesity?
por: Deng, Zhi-Jun, et al.
Publicado: (2018)

Metformin improves high-fat diet-induced insulin resistance in mice by downregulating the expression of long noncoding RNA NONMMUT031874.2
por: Zhang, Zhi-Mei, et al.
Publicado: (2022)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy
por: Kovács, Zsuzsanna Z. A., et al.
Publicado: (2021)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7mf4vus091coik4bomgh2h3v6f